Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

99results about "Reproductive system cancer vaccine" patented technology

Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
Owner:GENIMMUNE NV +1

Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof

The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Myeloid derived suppressor cell inhibiting agents

Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and / or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and / or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.
Owner:COLORADO STATE UNIVERSITY

Vector for anti-hpv vaccine and transformed microorganism by the vector

Expression vectors are described that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a Bacillus sp. strain, and genes that encode virion capsid proteins, tumor-associated proteins of human papillomavirus. Methodology for preparing the foregoing vectors, vaccines and transformed microorganisms are also described.
Owner:BIOLEADERS CORP

Extracellular matrix adjuvant & methods for prevention and/or inhibition of ovarian tumors and ovarian cancer

ActiveUS20110135690A1Improve anti-tumor activityEnhances immunizing and protective and anti-ovarian tumor physiological benefitCancer antigen ingredientsReproductive system cancer vaccineAdjuvantCell-Extracellular Matrix
Compositions suitable for use as ovarian cancer and / or tumor adjuvants in the preparation of ovarian cancer vaccines, particularly those vaccines useful in the treatment of human ovarian cancer, are provided. The ovarian cancer adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), tracer, or other solid or semi-solid preparation. Also disclosed are ovarian tumor inhibiting compositions that include extracellular matrix tissue adjuvants.
Owner:UNIV OF NOTRE DAME DU LAC

Human papillomavirus polypeptides and immunogenic compositions

The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides for fusions of HPV E6 and E7 in which the E6 and / or E7 contains one or more mutations. These mutations abrogate the transformation activity of these oncogenic proteins and, thus, confer safety to the E6 / E7 fusions. In addition, these fusions maintain or increase the immunogenic efficacy of E6 and E7. Any gene or protein delivery method can be used to deliver or package the immunogenic compositions of the present invention.
Owner:WYETH HOLDINGS LLC

Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder

The invention is relative to novel means of systemic or mucosal vaccinial therapy against some cancers, viral infections and allergy which are provided by the invention under the form of a family of composite superimmunogenic compounds for bifunctional vaccinial use able to induce an immune response raised towards two distinct targets, respectively, the causal pathogenic antigenic structure, on the one hand, and locally produced factors responsible for a subsequent immunotoxic or neoangiogenic stroma disorder, on the other hand.
Owner:NEOVACS SA

Fusion protein as well as preparation method and application thereof

The invention belongs to the immunotherapy and discloses a fusion protein as well as a preparation method and application thereof. The fusion protein disclosed by the invention comprises a protein HSP70 and a protein fused with an extracellular domain protein FPR1. The extracellular domain protein FPR1 comprises multiple amino acid sequences, and the amino acid sequences of different fragments ofthe extracellular domain protein FPR1 are connected by flexible linker peptides. The fusion protein disclosed by the invention is simple in preparation, high in specificity and long in duration time,and the immunotherapy effect can be obviously enhanced.
Owner:BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIV

Chimeric antigen receptor targeting NKG2D, chimeric antigen receptor T-cell targeting NKG2D and preparation method thereof and application thereof

The invention provides a chimeric antigen receptor (CAR) targeting NKG2D. Amino acid sequences of the CAR targeting NKG2D comprises the amino acid sequences of a single-chain antibody targeting NKG2D,an extracellular hinge region, a transmembrane region and an intracellular signal region which are sequentially connected from an amino terminal to a carboxyl terminal, respectively. The single-chainantibody targeting NKG2D comprises the amino acid sequences shown in SEQ ID NO: 1. The invention also provides a chimeric antigen receptor T-cell (CAR-T) targeting NKG2D and a preparation method thereof, as well as application of the CAR targeting NKG2D and the CAR-T targeting NKG2D in the prevention, diagnosis and treatment of liver cancer, cervical cancer, pancreatic cancer and other malignanttumors.
Owner:SHENZHEN BINDEBIOTECH CO LTD

Specific chimeric antigen receptor T cell targeting nkg2dl, preparation method and application thereof

A specific chimeric antigen receptor targeting NKG2DL, its coding sequence, and modified immune response cells, as well as their preparation method and application. The modified immune response cells can effectively target and attack various tumor cells, especially positive tumor cells expressing NKG2DL, and can be used to prepare preparations for treating tumors.
Owner:NANJING KAEDI BIOTHERAPEUTICS LTD

Myeloid derived suppressor cell inhibiting agents

Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and / or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and / or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.
Owner:COLORADO STATE UNIVERSITY

Double-chimeric antigen receptor, T cell and construction method and application thereof

The invention discloses a double-chimeric antigen receptor, a T cell and a construction method and an application thereof, which belong to the field of cellular immunotherapy of tumors. The inventionspecifically relates to a specific structure and a construction method of the double chimeric antigen receptor T cell (dCAR-T cell), and preliminarily discusses the in-vivo and in-vitro activity of the dCAR-T cell. The selected tumor-associated antigens are mesothelin and carcino-embryonic antigens, and researches show that the two tumor antigens can be simultaneously expressed on the surface of asolid tumor, such as pancreatic cancer. The invention discloses an antigen receptor. The in-vitro and in-vivo tests prove that the constructed dCAR-T cell can be permanently and effectively activatedonly under the condition that two antigens are simultaneously recognized, and has efficient anti-tumor activity, so that a specific tumor killing function can be exerted, and the application of CAR-Tcell immunotherapy is improved.
Owner:CHINA PHARM UNIV

Peripheral blood TCR marker for cervical cancer as well as detection kit and application of peripheral blood TCR marker

The invention discloses a peripheral blood TCR marker for cervical cancer as well as a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of which the sequences are shown as SEQ ID NO. 1-100. The method is based on a high-throughput sequencing method; only a small amount of peripheral blood needs to be collected; the method comprises thefollowing steps: extracting RNA, treating samples to establish an immune map library, carrying out high-throughput sequencing and TCR data analysis, firstly determining a characteristic TCR sequencein the peripheral blood of cervical cancer, and then comparing a test result of a sample to be tested with the characteristic TCR sequence so as to determine whether a patient suffers from the cervical cancer or not. According to the present invention, the huge number of the cervical cancer specific TCR sequences can be simultaneously compared, and compared to the single detection of one or more markers, the high specificity and the high accuracy are provided, and the diagnosis efficiency is improved.
Owner:CHENGDU EXAB BIOTECH CO LTD

Recombinant protein and medicine composition and application thereof

The invention relates to the field of biological medicine, in particular to recombinant protein, a medicine composition and application thereof. The recombinant protein comprises human papilloma virus E6 and E7 plasmodium fusion polypeptides, has specific amino acid sequences, and special space structures, so that strong immunogenicity, particularly cell-mediated immunity can be realized; the human body safety problem is solved through point mutation. The medicine composition provided by the invention comprises the recombinant protein and auxiliary agents, and can stimulate and reinforce the specific T-cell immune response aiming at the human papilloma virus E6 and E7 protein, can be used for effectively treating cervical cancer, and has good application prospects.
Owner:南京益康生物医药有限公司

Canine tumor cell and allogeneic dendritic cell fused vaccine and method for preparing the same

The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.
Owner:NAT TAIWAN UNIV

Compositions and methods for treating human papillomavirus-mediated disease

The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to a the age of the recipient, as well as the use of the composition to elicit a cross-reactive anti-HPV immune response.
Owner:EISAI INC

Chimeric antigen receptor of cell for targeted expression of Claudin 18.2 and application of chimeric antigen receptor

ActiveCN113354739AEfficient killingStrong killing and cytokine release functionVirusesAntibody mimetics/scaffoldsAntigenSingle-Chain Antibodies
The invention discloses a chimeric antigen receptor of a cell for targeted expression of Claudin 18.2 (CLDN 18.2), and particularly discloses a chimeric antigen receptor with an amino acid sequence as shown in SEQ ID NO.14. The chimeric antigen receptor comprises a Claudin 18.2-targeted single-chain antibody, a hinge region, a transmembrane structural domain and an intracellular signal structural domain. The Claudin 18.2-targeted chimeric antigen receptor disclosed by the invention can achieve effective and specific targeted expression of malignant cells (such as tumor cells) of the Claudin 18.2 surface antigen, so that a more efficient method with fewer side effects and adverse reactions is provided for treating some tumors expressing the Claudin 18.2 surface antigen.
Owner:SHANGHAI LIFE SCI & TECH CO LTD

Chimeric antigen receptor T lymphocyte and application thereof to preparation of product for treating solid tumors

The invention discloses a chimeric antigen receptor T lymphocyte and an application thereof to preparation of a product for treating solid tumors. A chimeric antigen receptor in the chimeric antigen receptor T lymphocyte sequentially comprises a human CD8 lead peptide, an anti-Siglec-15 single-chain antibody, a human CD8 hinge transmembrane region, a human 4-1BB intracellular region, a human CD3 zeta intracellular region, a self-cleavage peptide, a CSF2Ra signal peptide, an EGFRt protein, a self-cleavage peptide and a human CD27. Experiments prove that the chimeric antigen receptor T lymphocyte provided by the invention highly expresses IFN gamma and CD107a, has a strong killing function on Siglec-15 positive tumor cells, and has killing efficiency of more than 80% under the condition thatthe effect-target ratio is 1: 1. A tumor transplantation model experiment shows that the chimeric antigen receptor T lymphocyte also has a strong killing function on Siglec-15 positive tumor cells inan animal body.
Owner:CARBIOGENE THERAPEUTICS CO LTD

Composition and method of using carcinoma tumor cells

The present invention is directed to compositions and methods of treating cancer. The compositions of the present invention include a composition prepared from a tumor cell which is hapten modified and syngeneic to the type of tumor to be treated. The composition has the properties, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of said human, of eliciting an inflammatory immune response against the tumor of said human, and of eliciting a delayed-type hypersensitivity response to the tumor of said human. The methods of the present invention are directed to treating cancer comprising administering a therapeutically effective amount of a composition comprising a tumor cell.
Owner:THOMAS JEFFERSON UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products